DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

Hiu Lam Agnes Yuen, Michael Sze Yuan Low, Pasquale Fedele, Anna Kalff, Patricia Walker, Krystal Bergin, John Coutsouvelis, George Grigoriadis, Andrew Spencer

Research output: Contribution to journalArticleResearchpeer-review

Abstract

There is limited data describing dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in relapsed refractory multiple myeloma (RRMM). We reviewed 65 patients with RRMM receiving DCEP between 2005 and 2017 in two Melbourne Hospitals. Patients had received a mean of three prior treatment lines (range, 1–11). The mean number of cycles of DCEP was two (range, 1–4). Overall response rate (ORR) was 55% whilst 19% achieved MR and SD. Median overall survival (OS) was 9.6 months. Those bridged to autologous stem cell transplant (ASCT) had significantly improved OS compared to those who were not (median 32.8 vs. 10.7 months, p=.0004). Significant treatment-related mortality (TRM) was observed (9.7%), mostly attributable to grade 3–4 neutropenia and febrile neutropenia. Mandatory use of G-CSF is, therefore, warranted to prevent septic complications. In heavily pretreated RRMM, DCEP is an effective bridge to definitive therapy but in the absence of the latter, its value is questionable.

Original languageEnglish
Number of pages5
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - 5 Apr 2018

Keywords

  • chemotherapeutic approaches
  • DCEP
  • multiple myeloma
  • Relapsed/refractory
  • salvage chemotherapy

Cite this

Yuen, Hiu Lam Agnes ; Low, Michael Sze Yuan ; Fedele, Pasquale ; Kalff, Anna ; Walker, Patricia ; Bergin, Krystal ; Coutsouvelis, John ; Grigoriadis, George ; Spencer, Andrew. / DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. In: Leukemia and Lymphoma. 2018.
@article{5c3b7c784fd44e6da226556ec9aec479,
title = "DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma",
abstract = "There is limited data describing dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in relapsed refractory multiple myeloma (RRMM). We reviewed 65 patients with RRMM receiving DCEP between 2005 and 2017 in two Melbourne Hospitals. Patients had received a mean of three prior treatment lines (range, 1–11). The mean number of cycles of DCEP was two (range, 1–4). Overall response rate (ORR) was 55{\%} whilst 19{\%} achieved MR and SD. Median overall survival (OS) was 9.6 months. Those bridged to autologous stem cell transplant (ASCT) had significantly improved OS compared to those who were not (median 32.8 vs. 10.7 months, p=.0004). Significant treatment-related mortality (TRM) was observed (9.7{\%}), mostly attributable to grade 3–4 neutropenia and febrile neutropenia. Mandatory use of G-CSF is, therefore, warranted to prevent septic complications. In heavily pretreated RRMM, DCEP is an effective bridge to definitive therapy but in the absence of the latter, its value is questionable.",
keywords = "chemotherapeutic approaches, DCEP, multiple myeloma, Relapsed/refractory, salvage chemotherapy",
author = "Yuen, {Hiu Lam Agnes} and Low, {Michael Sze Yuan} and Pasquale Fedele and Anna Kalff and Patricia Walker and Krystal Bergin and John Coutsouvelis and George Grigoriadis and Andrew Spencer",
year = "2018",
month = "4",
day = "5",
doi = "10.1080/10428194.2018.1454595",
language = "English",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis",

}

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. / Yuen, Hiu Lam Agnes; Low, Michael Sze Yuan; Fedele, Pasquale; Kalff, Anna; Walker, Patricia; Bergin, Krystal; Coutsouvelis, John; Grigoriadis, George; Spencer, Andrew.

In: Leukemia and Lymphoma, 05.04.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

AU - Yuen, Hiu Lam Agnes

AU - Low, Michael Sze Yuan

AU - Fedele, Pasquale

AU - Kalff, Anna

AU - Walker, Patricia

AU - Bergin, Krystal

AU - Coutsouvelis, John

AU - Grigoriadis, George

AU - Spencer, Andrew

PY - 2018/4/5

Y1 - 2018/4/5

N2 - There is limited data describing dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in relapsed refractory multiple myeloma (RRMM). We reviewed 65 patients with RRMM receiving DCEP between 2005 and 2017 in two Melbourne Hospitals. Patients had received a mean of three prior treatment lines (range, 1–11). The mean number of cycles of DCEP was two (range, 1–4). Overall response rate (ORR) was 55% whilst 19% achieved MR and SD. Median overall survival (OS) was 9.6 months. Those bridged to autologous stem cell transplant (ASCT) had significantly improved OS compared to those who were not (median 32.8 vs. 10.7 months, p=.0004). Significant treatment-related mortality (TRM) was observed (9.7%), mostly attributable to grade 3–4 neutropenia and febrile neutropenia. Mandatory use of G-CSF is, therefore, warranted to prevent septic complications. In heavily pretreated RRMM, DCEP is an effective bridge to definitive therapy but in the absence of the latter, its value is questionable.

AB - There is limited data describing dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in relapsed refractory multiple myeloma (RRMM). We reviewed 65 patients with RRMM receiving DCEP between 2005 and 2017 in two Melbourne Hospitals. Patients had received a mean of three prior treatment lines (range, 1–11). The mean number of cycles of DCEP was two (range, 1–4). Overall response rate (ORR) was 55% whilst 19% achieved MR and SD. Median overall survival (OS) was 9.6 months. Those bridged to autologous stem cell transplant (ASCT) had significantly improved OS compared to those who were not (median 32.8 vs. 10.7 months, p=.0004). Significant treatment-related mortality (TRM) was observed (9.7%), mostly attributable to grade 3–4 neutropenia and febrile neutropenia. Mandatory use of G-CSF is, therefore, warranted to prevent septic complications. In heavily pretreated RRMM, DCEP is an effective bridge to definitive therapy but in the absence of the latter, its value is questionable.

KW - chemotherapeutic approaches

KW - DCEP

KW - multiple myeloma

KW - Relapsed/refractory

KW - salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85044975855&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1454595

DO - 10.1080/10428194.2018.1454595

M3 - Article

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -